• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer
  • Advertise
  • Subscribe

Drug Delivery Business

  • Clinical Trials
  • Research & Development
  • Drug-Device Combinations
  • FDA
  • Pharmaceuticals
  • Policy

Reva touts first implant of bioresorbable scaffold in Turkey

May 16, 2018 By Sarah Faulkner

Reva MedicalReva Medical (ASX:RVA) said today that the company launched its Fantom bioresorbable scaffold in Turkey.

There are nearly 100 hospitals performing cardiac catheterizations in Istanbul, according to Reva. The San Diego, Calif.-based company highlighted Turkey as an important market for bioresorbable technologies, noting that it has a commercial distribution deal in the country with Kardionet Healthcare and Foreign Trading.

The first implants of Reva’s Fantom device occurred at three hospitals in Turkey. The procedures were performed by Bilal Boztosun, chief of cardiology at the Mega Medipol University Hospital, Ömer Göktekin, chief of cardiology at the Memorial B. Evler Hospital and Ismail Ates, chief of cardiology at the Medical Park Hospital.

Reva’s second-generation bioresorbable scaffold, the Fantom device, is made from a proprietary polymer that improves ease-of-use and gives the product a thinner profile and full x-ray visibility, the company touted.

“During the implant procedure I was impressed with how easy Fantom was able to be delivered to the target location in comparison to first generation bioresorbable scaffolds,” Boztosun said in prepared remarks. “The x-ray visibility enabled me to visualize Fantom and accurately place the device with ease.”

“Our experience with Kardionet so far indicates that we chose the right partner for commercialization in Turkey,” CEO Reggie Groves added. “We have hit all of our second quarter milestones including local registration approval, training, product shipments, and now the first implants. The successful approach we have established in Turkey will be our model for several additional commercial distribution partnerships we plan to initiate in the next six to 12 months.”

Reva is positioning its sirolimus-eluting scaffold as an alternative to metallic stents for the treatment of coronary artery disease.

Want to stay on top of DDBN content? Sign up for our e-mail newsletter for a weekly dose of drug-device news.

Filed Under: Drug-Device Combinations, Featured, Implants, Pharmaceuticals, Vascular, Wall Street Beat Tagged With: Reva Medical

IN CASE YOU MISSED IT

  • Insulet hires new chief HR officer from J&J
  • Breakthrough T1D, Mattel debut Barbie doll with type 1 diabetes
  • Medtronic Diabetes names CFO with consumer experience ahead of separation
  • Diabeloop launches insulin delivery algorithm in Germany
  • GlucoModicum has positive data for needle-free CGM

Primary Sidebar

“ddb
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in drug delivery.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.

Footer

Drug Delivery Business News Logo

MassDevice Medical NETWORK

MassDevice
DeviceTalks
Medical Tubing + Extrusion
Medical Design & Outsourcing
MedTech100 Index
Drug Discovery & Development
Pharmaceutical Processing World
Medical Design Sourcing
R&D World

DRUG DELIVERY BUSINESS NEWS

Subscribe to Drug Delivery’s E-Newsletter
Advertise with us
About
Contact us
Privacy
Listen to our Weekly Podcasts

Copyright © 2025 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Privacy Policy | RSS